v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities:    
Net loss $ (33,701) $ (33,011)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation expense 2,953 3,892
Non-cash interest expense on unsecured convertible debt 477 446
Depreciation and amortization 186 278
Non-cash interest earned on OMIDRIA contract royalty asset (3,925) (4,838)
Remeasurement on OMIDRIA contract royalty asset (1,677) (2,158)
Accretion on U.S. government treasury bills, net (2,316)  
Early termination of operating lease   (454)
Changes in operating assets and liabilities:    
Receivables 203,188 21,900
Prepaid expenses and other (582) 592
OMIDRIA contract royalty asset 9,203 13,831
Accounts payable and accrued expense 733 (15,671)
Net cash provided by (used in) operating activities 174,539 (15,193)
Investing activities:    
Purchases of investments (523,941) (83,013)
Proceeds from the sale and maturities of investments 342,610 6,200
Net cash used in investing activities (181,331) (76,813)
Financing activities:    
Principal payments on OMIDRIA royalty obligations (278)  
Principal payments on finance lease obligations (110) (253)
Proceeds upon exercise of stock options and warrants   414
Net cash provided by (used in) financing activities (388) 161
Net decrease in cash and cash equivalents (7,180) (91,845)
Cash and cash equivalents at beginning of period 11,009 100,808
Cash and cash equivalents at end of period 3,829 8,963
Supplemental cash flow information    
Cash paid for interest $ 7,933 $ 5,967